Guardant Health (GH)
NASDAQ:GH
Want to see GH full AI Analyst Report?
GH Stock Chart & Stats
$90.36
$0.91(2.52%)
At close: 4:00 PM EST
$90.36
$0.91(2.52%)
Day’s Range― - ―
52-Week Range$39.70 - $133.97
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.24M
Market Cap
$17.20B
Enterprise Value$17.88B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$1.68B
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Jul 30, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding132,599,930
10 Day Avg. Volume2,643,635
30 Day Avg. Volume2,237,751
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue16.56
Enterprise Value/Gross Profit25.51
Enterprise Value/Ebitda-45.74
Forecast
1Y Price Target
$131.73Price Target Upside45.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.93
Revenue Forecast (FY)$1.31B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & GuidanceSustained top-line momentum and raised full-year guidance indicate scalable demand across Oncology, Biopharma & Screening. Volume-led growth (>35% oncology volume guidance) suggests structural adoption, supporting multi‑quarter revenue durability as tests and partnerships scale.
Margin Expansion Via Sequencing Cost CutsLower sequencing costs materially improve per-test economics and underlie a sustainable gross margin profile (guidance 64–65%). Durable cost reductions plus scale reduce variable costs for liquid biopsy and screening, improving the path to structural profitability as volumes grow.
Large Data Treasury & PartnershipsA substantial data asset base and validated CDx footprint create a defensible competitive advantage for AI models, RWE and regulatory submissions. Long‑term partnerships and approvals deepen commercial moats and support recurring Biopharma & clinical revenue streams.
Bears Say
High Leverage & Negative EquityElevated debt and negative equity constrain financial flexibility and increase refinancing and covenant risk. Until sustained profitability and retained earnings rebuild equity, balance-sheet leverage limits strategic optionality and raises sensitivity to funding cost changes.
Persistent Cash Burn & LossesMaterial negative operating and free cash flow indicate the business still consumes cash despite improvement. Continued reliance on external capital or profitable unit ramp is required to reach company-wide breakeven by 2027, creating execution and funding risk over coming quarters.
Rising Operating ExpensesAggressive reinvestment to scale Shield and commercial footprint has raised the fixed cost base. If adoption, reimbursement or regulatory timing lags, higher S&M and operating spend could delay margin recovery and amplify cash burn over multiple quarters.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $39.70 and its highest was $133.97 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $17.20B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 07, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.806 by -$0.044.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.76.
How many shares outstanding does Guardant Health have?
Guardant Health has 132,599,930 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.806. Following the earnings report the stock price went up 3.729%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.73 (45.79% Upside)
$131.73 (45.79% Upside)
Blogger Sentiment
Bullish
GH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 808.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $40.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Bullish
Bullish news 79%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
236.42%
12-Months-Change
Fundamentals
Return on Equity
184.27%
Trailing 12-Months
Asset Growth
42.48%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Company Deck
GH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and commercial quarter: revenue growth was robust across Oncology, Biopharma & Data and Screening, Shield showed breakout traction with meaningful margin improvement, and product and data investments (InfinityAI, NovaSeq X transition, expanded FDA approvals and partnerships) support multi-year upside. Key near-term challenges include elevated operating expenses to fund growth, ongoing adjusted losses and free cash flow burn, and dependencies on reimbursement and third-party regulatory outcomes (MolDx reviews, drug approvals) that introduce timing and upside uncertainty. Overall, positives (accelerating revenue, volume, margin improvement, data/AI progress, and strengthened partnerships) materially outweigh the risks, though execution and reimbursement milestones remain important to sustain momentum.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$131.73
▲(45.79% Upside)
Technical Analysis
Ownership Overview
3.36% Insiders
32.43% Mutual Funds
35.53% Other Institutional Investors
13.11% Public Companies and
Individual Investors